Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To analyse the impact of late-line treatment (regorafenib (REGO) or trifluridine/tipiracil (FTD/TPI) on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer

Next Previous
X
Search
Trial Profile

To analyse the impact of late-line treatment (regorafenib (REGO) or trifluridine/tipiracil (FTD/TPI) on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary) ; Antineoplastics
  • Indications Colorectal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 21 Sep 2020 Results (data cut off date-Dec 2019) of updated analysis assessing impact of late-line treatment on overall survival from the initiation of first line chemotherapy for patients with metastatic colorectal cancer, presented at the 45th European Society for Medical Oncology Congress
    • 14 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top